Search Result

Results for "

LPA2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Caspase (1) LPL Receptor (15) Phosphodiesterase (PDE) (1) Reference Standards (1) ROCK (1) Small Interfering RNA (siRNA) (2) TGF-beta/Smad (1) TGF-β Receptor (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (5) Neurological Disease (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18075

LPA2 antagonist 1 4 Publications Verification	LPL Receptor	Cancer
LPA2 antagonist 1 is a *LPA2* antagonist with an IC₅₀ of 17 nM.

HY-113973

LPA2 antagonist 2	LPL Receptor	Cancer
LPA2 antagonist 2 (H2L 5226501) is a selective *LPA₂* antagonist with an IC₅₀ of 28.3 nM and a K_i of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA₃ (IC₅₀ of 13.85 μM) .

HY-107616

H2L5186303 3 Publications Verification	LPL Receptor Apoptosis	Inflammation/Immunology
H2L5186303 is a potent and selective *LPA₂* receptor antagonist with an IC₅₀ of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects ^[2] .

HY-114379

AS2717638 2 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀ value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases ^[2].

HY-100676

GRI977143	LPL Receptor Caspase	Inflammation/Immunology Cancer
GRI977143 is a specific LPA₂ receptor agonist, with an EC₅₀ of 3.3 μM .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype .

HY-117779

DBIBB 2 Publications Verification	Apoptosis	Endocrinology
DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .

HY-173324

LPA2 antagonist 5	LPL Receptor	Others
LPA2 antagonist 5 (EX1) is a *LPA2* antagonist, with an IC₅₀ of 4.05 nM .

HY-173325

LPA2 antagonist 6	LPL Receptor	Cardiovascular Disease
LPA2 antagonist 6 (example 2) is an antagonist of Lp(a). LPA2 antagonist 6 inhibits Lp(a) formation with an IC₅₀ value of 2.33 nM. LPA2 antagonist 6 can be used in the research of cardiovascular disease .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor	Neurological Disease Cancer
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates *LPA₁* and *LPA₂, thereby triggering calcium mobilization, NFATc1* translocation, Rho/ROCK activation, *Smad2/3* phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer ^[2] .

HY-148291

*BrP-LPA* sodium**	LPL Receptor Phosphodiesterase (PDE)	Cancer
BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against *LPA₁* (IC₅₀ = 4520 nM), *LPA₂* (IC₅₀ = 468 nM), *LPA₃, and LPA₄. BrP-LPA* sodium also has partial agonistic activity for *LPA₅, with its EC₅₀* being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer .

HY-118539

NSC12404	LPL Receptor	Others
NSC12404 is a weak and specific LPA₂ receptor agonist .

HY-171906A

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium 1-Arachidonoyl-sn-glycerol 3-phosphate sodium; 1-Arachidonoyl LPA sodium; LPA (20:4) sodium	LPL Receptor	Cancer
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) (1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)) is a phospholipid with arachifonic acid at the sn-1 position. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) binds to the *LPA₂/EDG4* receptor (EC₅₀ of 10 nM). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can be found in rat brain as 37% of the arachidoinic acid-containing lysophosphatidic acid species. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) is the precursor to 1-arachidonoyl glycerol. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can prevent TNF-α and IL-6 secretion in wild type LPS-stimulated dendritic cells. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) reduces differentiation of HT-29 colon carcinoma cells into goblet cells when sodium butyrate is present ^[2] .

HY-171906

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA 1-Arachidonoyl-sn-glycerol 3-phosphate; 1-Arachidonoyl LPA; LPA (20:4)	LPL Receptor	Inflammation/Immunology
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin; HY-130567) . 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM ^[2]. It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS . It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate .

HY-178845

Decyl phosphate Decyl dihydrogen phosphate	LPL Receptor	Cardiovascular Disease
Decyl phosphate is a selective *LPA₂* agonist (EC₅₀: 1.8 μM) and *LPA₁/LPA₃* antagonist. Decyl phosphate can be used in the research of blood disorders .

HY-RS07749

LPAR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LPAR2 Human Pre-designed siRNA Set A contains three designed siRNAs for LPAR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LPAR2 Human Pre-designed siRNA Set A LPAR2 Human Pre-designed siRNA Set A

HY-RS07750

Lpar2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Lpar2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lpar2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lpar2 Mouse Pre-designed siRNA Set A Lpar2 Mouse Pre-designed siRNA Set A

HY-107616R

H2L5186303 (Standard)	Reference Standards LPL Receptor Apoptosis	Inflammation/Immunology
H2L5186303 (Standard) is the analytical standard of H2L5186303 (HY-107616). This product is intended for research and analytical applications. H2L5186303 is a potent and selective LPA2 receptor antagonist with an IC₅₀ of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects ^[2] .

Cat. No.	Product Name	Type

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	Fluorescent Dye
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates *LPA₁* and *LPA₂, thereby triggering calcium mobilization, NFATc1* translocation, Rho/ROCK activation, *Smad2/3* phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer ^[2] .

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

Fluorescent Dye

1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA₁ and LPA₂, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer ^[2] .

Cat. No.	Product Name	Type

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	Biochemical Assay Reagents
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates *LPA₁* and *LPA₂, thereby triggering calcium mobilization, NFATc1* translocation, Rho/ROCK activation, *Smad2/3* phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer ^[2] .

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

Biochemical Assay Reagents

LPAR2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
LPAR2 Human Pre-designed siRNA Set A contains three designed siRNAs for LPAR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lpar2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Lpar2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lpar2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor	Neurological Disease Cancer
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates *LPA₁* and *LPA₂, thereby triggering calcium mobilization, NFATc1* translocation, Rho/ROCK activation, *Smad2/3* phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer ^[2] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.